CoreAge Rx vs Fifty 410
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Fifty 410 head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
Fifty 410
FDA warning letter, February 2026 — issued to Aspen Aesthetics dba Fifty 410. See the FDA's warning letter database.
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 66 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make Fifty 410 a bad call — it's best for readers comparing a four-week purchase with an eight-week supply who can confirm pharmacy assignment and the compounding cutoff. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | Fifty 410 |
|---|---|---|
| Brief Score | 94/100 (A) | 66/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | $199 / 4 weeks Total four-week program charge; consultation and shipping included as advertised. Four supplied weeks are not a calendar month; provider approval and pharmacy preparation apply. Full price detailsCalendar-month quote unknown; compounded semaglutide $199 total for a four-week program, including consultation and shipping |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | $199 / 4 weeks Eight-week alternative: $299 total ($149.50 per four weeks), with nine-state exclusions. Consultation and shipping included as advertised; confirm the state-eligible program. Full price detailsCalendar-month quote unknown; compounded tirzepatide $199 total for four weeks or $299 total for eight weeks ($149.50 per four weeks), with nine-state exclusions on the eight-week option |
| Coverage | US only; restrictions by state, confirmed at intake | Four-week programs advertised in all fifty states; eight-week tirzepatide excludes Alabama, Arkansas, California, Hawaii, Kansas, Massachusetts, Michigan, Minnesota and Mississippi |
| Brand-name access | Not confirmed | Reviewed current GLP-1 programs are compounded; branded fulfillment was not established. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
Fifty 410: Both drugs are $199 for four weeks. Tirzepatide also has an eight-week $299 option with state exclusions; $149.50 is its four-week average, not the amount charged.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.